In July 2021, Obseva licensed the exclusive worldwide rights to develop, manufacturing and commercial rights to ebopiprant (OBE022) to Organon, a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, to focus on improving the health of women throughout their lives. Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,000 employees with its headquarters located in Jersey City, New Jersey. Goldman Sachs acted as exclusive financial advisor to ObsEva
In November 2022, Xoma acquired the rights to ebopiprant from ObsEva, including the Organon License, Patent Estate, and Merck KGaA ,Darmstadt, Germany license Under the terms of the agreement, ObsEva is entitled to receive up to $113 million in upfront and milestone payments including $15 million which was paid at signing.
